Cross-sensitivity between paclitaxel and docetaxel in a women's cancers program (original) (raw)
Use of Docetaxel After Paclitaxel Hypersensitivity Reaction in Epithelial Ovarian and Endometrial Cancer
Kazuhiko Ochiai
Clinical Ovarian Cancer, 2009
View PDFchevron_right
Hypersensitivity reaction (HSR) to docetaxel after a previous HSR to paclitaxel
Ehtesham Abdi
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002
View PDFchevron_right
Hypersensitivity reaction (HSR) to docetaxel after previous HSR to paclitaxel
Ehtesham Abdi
Journal of Clinical Oncology
View PDFchevron_right
Hypersensitivity Reactions to the Taxanes Paclitaxel and Docetaxel
Manon Huizing
Clinical Drug Investigation, 1997
View PDFchevron_right
Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments
Anna Feldweg
Gynecologic Oncology, 2005
View PDFchevron_right
Feasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction
Maryam Lustberg
Supportive Care in Cancer, 2011
View PDFchevron_right
Universal tolerance of nab-paclitaxel for gynecologic malignancies in patients with prior taxane hypersensitivity reactions
Chad Michener
Journal of gynecologic oncology, 2017
View PDFchevron_right
Outpatient Administration of Paclitaxel
Siu-fun Wong
1994
View PDFchevron_right
A phase I clinical and pharmacokinetic study of paclitaxel and docetaxel given in combination in patients with solid tumours
Ramon Salazar
European Journal of Cancer, 2006
View PDFchevron_right
Comparison of Weekly Versus Every Three Weeks Adverse Effects of Paclitaxel as Adjuvant Chemotherapy in Breast Cancer Patients
Yasir Mehmood
View PDFchevron_right
Adverse reactions to docetaxel: an active survey
LEANDRO PEREIRA
Brazilian Journal of Pharmaceutical Sciences, 2015
View PDFchevron_right
Feasibility of withholding dexamethasone premedication for hypersensitivity reactions associated with paclitaxel administration
Thanapoom Rattananupong
Asian Biomedicine
View PDFchevron_right
Pathologic Response After Weekly Paclitaxel versus Docetaxel in Operable Breast Cancer
Paula Iuliana Toma
Cancer Management and Research, 2020
View PDFchevron_right
A phase II study of single agent paclitaxel in patients at first relapse following initial chemotherapy for breast cancer
Timothy Perren
Clinical Oncology, 1996
View PDFchevron_right
History of paclitaxel and oral paclitaxel – Clinical data and future
Ganesh Divekar
Indian Journal of Medical and Paediatric Oncology
View PDFchevron_right
Comparison of adverse events following injection of original or generic docetaxel for the treatment of breast cancer
HITOSHI SATO
Cancer Chemotherapy and Pharmacology, 2017
View PDFchevron_right
Docetaxel-induced skin toxicities in breast cancer patients subsequent to paclitaxel shortage: a case series and literature review
Maryam Lustberg
Supportive Care in Cancer, 2013
View PDFchevron_right
Drug interactions of paclitaxel and docetaxel and their relevance for the design of combination therapy
G. Grasselli
Investigational new drugs, 2001
View PDFchevron_right
A dose escalation study of weekly docetaxel in patients with advanced solid tumors
Stylianos Kakolyris
Cancer Chemotherapy and Pharmacology, 2000
View PDFchevron_right
Phase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously received paclitaxel—ANZGOG 02-01
Robin Stuart-harris
Gynecologic Oncology, 2007
View PDFchevron_right
Safety and Efficacy of the Multidrug Resistance Inhibitor Incel (Biricodar; VX-710) in Combination with Paclitaxel for Advanced Breast Cancer Refractory to Paclitaxel
Shailendra Verma
2002
View PDFchevron_right
Assessment of antihistamines and corticosteroids as premedication in rapid drug desensitization to paclitaxel: outcomes in 155 procedures
Ricardo Madrigal-Burgaleta
Journal of Allergy and Clinical Immunology: In Practice, 2017
View PDFchevron_right
Paclitaxel pharmacokinetics and response to chemotherapy in patients with advanced cancer treated with a weekly regimen
Dirk Behringer
Anticancer research
View PDFchevron_right
Scleroderma induced by paclitaxel
anders krarup-hansen
Acta Oncologica, 2010
View PDFchevron_right
Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer
Vicky Jones
New England Journal of Medicine, 2008
View PDFchevron_right
Development and validation of a method to determine the unbound paclitaxel fraction in human plasma
Samuel Carda-broch
Analytical Biochemistry, 2004
View PDFchevron_right
Signal Detection of Docetaxel in Canadian Spontaneous Adverse Event Reports
JPR Solutions
View PDFchevron_right
Weekly 1-hour infusion of paclitaxel
Lance Heilbrun
Cancer, 2000
View PDFchevron_right
Different in Vitro Metabolism of Paclitaxel and Docetaxel in Humans, Rats, Pigs, and Minipigs
Radka Václavíková
Drug Metabolism and Disposition, 2004
View PDFchevron_right
Efficacy and tolerability of weekly paclitaxel in combination with high-dose toremifene citrate in patients with metastatic breast cancer
Kenjiro Aogi
Acta Medica Okayama, 2009
View PDFchevron_right